Automated insulin delivery technology, also known as closed-loop systems or artificial pancreas, is increasingly used in diabetes management, particularly for type 1 diabetes. These systems automatically adjust insulin delivery based on real-time glucose levels, improving glucose control and reducing hypoglycaemia. Hybrid closed-loop systems require users to input meal information, while fully automated systems operate without such input. Real-world data show that these systems perform well in clinical practice, with improvements in glucose management and user satisfaction. Closed-loop systems have shown benefits for both type 1 and type 2 diabetes, though more research is needed for type 2. They are particularly useful for individuals with high insulin variability, such as adults with type 2 diabetes, very young children with type 1 diabetes, and pregnant women. These systems also offer psychosocial benefits, reducing diabetes-related stress and improving quality of life. Commercially available hybrid closed-loop systems include Medtronic 780G, Control-IQ, Diabeloop, CamAPS FX, Omnipod 5, and iLet bionic pancreas. Each has unique features and is suitable for different user groups. Real-world data indicate high user engagement and improved glucose control, though challenges remain in access, reimbursement, and user training. Despite their benefits, closed-loop systems face challenges in implementation, including regulatory hurdles, cost, and user acceptance. Future developments aim to improve device usability, expand interoperability, and enhance performance through advanced algorithms and technologies like artificial intelligence. Additionally, research is ongoing to address limitations in glucose management during meals and exercise, and to explore new insulin types and dual-hormone systems for better outcomes. Overall, closed-loop technology holds promise for improving diabetes care, but equitable access and further research are essential to maximize its benefits for all patients.Automated insulin delivery technology, also known as closed-loop systems or artificial pancreas, is increasingly used in diabetes management, particularly for type 1 diabetes. These systems automatically adjust insulin delivery based on real-time glucose levels, improving glucose control and reducing hypoglycaemia. Hybrid closed-loop systems require users to input meal information, while fully automated systems operate without such input. Real-world data show that these systems perform well in clinical practice, with improvements in glucose management and user satisfaction. Closed-loop systems have shown benefits for both type 1 and type 2 diabetes, though more research is needed for type 2. They are particularly useful for individuals with high insulin variability, such as adults with type 2 diabetes, very young children with type 1 diabetes, and pregnant women. These systems also offer psychosocial benefits, reducing diabetes-related stress and improving quality of life. Commercially available hybrid closed-loop systems include Medtronic 780G, Control-IQ, Diabeloop, CamAPS FX, Omnipod 5, and iLet bionic pancreas. Each has unique features and is suitable for different user groups. Real-world data indicate high user engagement and improved glucose control, though challenges remain in access, reimbursement, and user training. Despite their benefits, closed-loop systems face challenges in implementation, including regulatory hurdles, cost, and user acceptance. Future developments aim to improve device usability, expand interoperability, and enhance performance through advanced algorithms and technologies like artificial intelligence. Additionally, research is ongoing to address limitations in glucose management during meals and exercise, and to explore new insulin types and dual-hormone systems for better outcomes. Overall, closed-loop technology holds promise for improving diabetes care, but equitable access and further research are essential to maximize its benefits for all patients.